American journal of respiratory and critical care medicine
-
Am. J. Respir. Crit. Care Med. · Oct 2024
Efficacy and Safety of Admilparant, an LPA1 Antagonist in Pulmonary Fibrosis: A Phase 2 Randomized Clinical Trial.
Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) have high morbidity and mortality; thus, novel treatments are needed. ⋯ gov, ID: NCT04308681.